Loading organizations...
Loading organizations...
Limbix is a technology company.
Limbix develops prescription digital therapeutics designed to address adolescent mental health challenges. Its primary product, SparkRx, employs principles of cognitive behavioral therapy delivered digitally to treat depression in teens and young adults. The company focuses on creating evidence-based, clinically validated interventions to expand access to mental healthcare for a vulnerable demographic.
Limbix was founded in 2016 by Ben Lewis, Jonathan Sockell, and Scott Satkin. The co-founders recognized a significant unmet need for scalable and accessible mental health treatment options specifically tailored for adolescents, a demographic often underserved by traditional care models. Their insight centered on leveraging technology to deliver therapeutic interventions directly to young people.
The company primarily serves adolescents and young adults experiencing depression, aiming to provide a pathway to support that is often more readily available and less stigmatizing than conventional methods. Limbix's long-term vision is to democratize mental health treatment, ensuring that effective, personalized care reaches young people whenever and wherever they need it.
Limbix has raised $30.6M across 4 funding rounds.
Limbix has raised $30.6M in total across 4 funding rounds.
Limbix is a technology company specializing in prescription digital therapeutics for adolescent mental health, developing evidence-based mobile apps like SparkRx to address depression symptoms as adjunct treatments.[1][2][3] It serves teens aged 13-21 and licensed healthcare professionals, solving access barriers to mental health care post-diagnosis through self-guided, clinically validated cognitive behavioral therapy (CBT) programs delivered via secure mobile platforms.[2][5][6] Limbix built the Limbix Synapse platform for rapid development, testing, and deployment of compliant digital therapeutics, enabling global customization and clinical trials; SparkRx demonstrated clinically meaningful symptom reductions in trials with 63-86 patients.[1][3] Founded in 2016, it raised $27.08M before being acquired by Big Health in July 2023, integrating SparkRx into Big Health's portfolio alongside products for insomnia and anxiety.[3][4]
Limbix was founded in 2016 in Palo Alto, California (later associated with San Francisco), by Ben Lewis (Co-Founder & CEO, former Facebook Engineering Manager), Jon Sockell (Co-Founder & COO, former Motive Marketing Director), Judy Liu (CTO, former Facebook Software Engineer), and Aarthi Padmanabhan, Ph.D., a team blending clinical, design, research, engineering, and tech expertise to innovate mental health treatments for underserved teens.[3][4] The idea emerged from recognizing adolescents' post-diagnosis care gaps—many see pediatricians but lack follow-up—spurred by rising mental health needs, amplified during COVID-19.[5] Early traction included teen focus groups shaping SparkRx's interface (e.g., colors, Limbot avatar), a 30-participant feasibility study in 2019, a 235-participant pandemic trial, and 2021 data release showing significant depression reductions versus controls, presented at the American Academy of Pediatrics conference.[5][6] By 2022, Limbix launched Synapse and made SparkRx available nationwide to professionals; it raised $9M in Series A (2020, led by GSR Ventures) toward $27M total before Big Health's 2023 acquisition.[1][4][6]
Limbix rides the digital therapeutics (DTx) wave in mental health, targeting adolescent gaps amid surging demand—exacerbated by COVID-19 isolation and chronic youth access issues—within a market innovating prescription software for disorders like depression and anxiety.[4][5][6] Timing aligns with DTx infrastructure growth (e.g., platforms like DTx Connect for EMR integration, ordering), regulatory progress toward FDA approvals, and Big Health's acquisition ecosystem expanding validated tools beyond pharma.[1][4] Favorable forces include clinician shortages, telehealth normalization, and evidence demands for non-drug adjuncts; Limbix influences by validating teen-specific DTx (e.g., SparkRx data), advancing Synapse for multi-therapeutic pipelines, and boosting Big Health's youth portfolio, catalyzing scalable, equitable mental health tech.[3][4][6]
Post-2023 Big Health acquisition, Limbix's Synapse and SparkRx will likely accelerate integration into broader DTx portfolios, targeting FDA approval for prescription status and expanding to anxiety therapeutics in development.[4][6] Shaping trends—AI-enhanced personalization, global DTx adoption, value-based care—favor its platform for rapid iteration amid youth mental health crises. Its influence may evolve by standardizing evidence-based adolescent DTx, powering Big Health's growth and inspiring clinician-led innovation, ultimately delivering accessible tech where traditional care falls short—just as its origins envisioned.[1][3][5]
Limbix has raised $30.6M in total across 4 funding rounds.
Limbix's investors include GSR Ventures, Bixink, Digital Garage, DN Capital, e& capital, Gaingels, Korea Investment Partners, Mana Ventures, MVP Ventures, Operator Partners, Pacific Health Ventures, Storm Ventures.
Limbix has raised $30.6M across 4 funding rounds. Most recently, it raised $15.0M Series A in December 2021.